Compare EPM & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPM | STTK |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 119.0M |
| IPO Year | 1996 | 2020 |
| Metric | EPM | STTK |
|---|---|---|
| Price | $3.52 | $3.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $4.75 | $4.00 |
| AVG Volume (30 Days) | ★ 427.7K | 392.9K |
| Earning Date | 11-11-2025 | 11-06-2025 |
| Dividend Yield | ★ 13.60% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,232,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.51 | $0.69 |
| 52 Week High | $5.70 | $3.38 |
| Indicator | EPM | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 25.80 | 67.21 |
| Support Level | $4.02 | $2.82 |
| Resistance Level | $3.85 | $3.30 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 1.32 | 74.76 |
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.